Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Public ClinicalTrials.gov record NCT06345404. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Study identification
- NCT ID
- NCT06345404
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2024 (Actual)
- Primary completion
- Jan 28, 2026 (Actual)
- Completion
- Feb 24, 2026 (Actual)
- Last update posted
- Mar 12, 2026
2024 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site 5 | Birmingham | Alabama | 35244 | — |
| Clinical Site 9 | Tucson | Arizona | 85704 | — |
| Clinical Site 3 | North Little Rock | Arkansas | 72117 | — |
| Clinical Site 2 | Fremont | California | 94538 | — |
| Clinical Site 7 | Palo Alto | California | 94063 | — |
| Clinical Site 13 | Pomona | California | 91767 | — |
| Clinical Site 10 | Castle Rock | Colorado | 80109 | — |
| Clinical Site 6 | Tampa | Florida | 33615 | — |
| Clinical Site 11 | Brooklyn | New York | 11203 | — |
| Clinical Site 16 | New York | New York | 10023 | — |
| Clinical Site 12 | New York | New York | 10075 | — |
| Clinical Site 15 | Mayfield Heights | Ohio | 44124 | — |
| Clinical Site 1 | Camp Hill | Pennsylvania | 17011 | — |
| Clinical Site 8 | Philadelphia | Pennsylvania | 19103 | — |
| Clinical Site 4 | Frisco | Texas | 75034 | — |
| Clinical Site 14 | San Antonio | Texas | 78213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06345404, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06345404 live on ClinicalTrials.gov.